Indian authorities have implemented new trade margin caps on 137 cancer medications, effective November 9, 2026. GSK's oncology drug Jemperli was evaluated under these new regulations and did not receive a price cut, indicating a neutral impact on this specific product for the company.
India has introduced new trade margin caps on 137 cancer medications, effective November 9, 2026. This regulatory change could significantly impact pharmaceutical companies operating in India with oncology portfolios. However, GSK's oncology drug Jemperli was specifically evaluated and found not to be subject to a price cut, as its manufacturer price remains unchanged. This is a neutral development for GSK regarding Jemperli, as it avoids potential revenue loss from this specific product. The long-term implications for GSK's broader portfolio in India, and for other pharmaceutical companies, will depend on how other drugs are assessed under these new regulations.